

26 October 2023

Wilsons Drug and Device Conference Presentation

Mach7 Technologies Limited (“M7T” or “the Company”) (ASX:M7T), a company specialising in innovative imaging software solutions, today provides a copy of a presentation that will be delivered by the CEO Mike Lampron at the 2023 Wilsons Drug and Device Conference tomorrow 27 October.

Released on authority of the Board by:

Mike Lampron
Managing Director and Chief Executive Officer

For more information, contact:

Investor Relations

Françoise Dixon
+61 (0) 412 292 977
ir@mach7t.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T), founded in 2007, is a medical imaging systems provider that develops innovative image management and viewing solutions for healthcare organizations. The core of these offerings is the Mach7 Enterprise Imaging Solution, encompassing Enterprise Data Management, Enterprise Diagnostic Viewing and Departmental Workflow applications. Mach7's Enterprise Data Management solution, consisting of a powerful Vendor Neutral Archive (VNA) and data administration tools, allows for the fast storage, access, retrieval and viewing of images across a healthcare network with connectivity to the Cloud. In July 2020, Mach7 acquired Client Outlook and the eUnity Enterprise Diagnostic Viewing technology to augment Mach7's Enterprise Data Management and Departmental Workflow applications. eUnity is a zero-footprint, FDA-approved, image viewing solution that makes images accessible on any workstation. This offers healthcare professionals consolidated access to all patient images and data, ensuring clinical staff have timely access to the right information to diagnose and treat patients. Uniquely, the company also gives customers independence to deploy its solutions either on a component basis or in a unified comprehensive platform. With more than 165 customers across 15 different countries, Mach7 has built a global network of diverse customers that range from expansive Integrated Delivery Networks, National Health Systems, medical research facilities, and large academic medical institutions to regional community hospitals, private radiology practices, and independent provider groups. Visit [Mach7t.com](https://www.mach7t.com).



Wilsons Drug and Device
Conference Presentation

Enterprise Imaging Session

October 2023

Mach7 Technologies
ASX: M7T

Mach7 Technologies develops innovative image management and viewing solutions that form the core of an integrated enterprise imaging ecosystem.

Enterprise Imaging refers to a set of strategies, initiatives and workflows implemented across a healthcare enterprise to consistently and optimally capture, index, manage, store, distribute, view, exchange, and analyse all clinical imaging and multimedia content to enhance the electronic health record.¹



Fragmentation

- Fragmented imaging market with long-time legacy vendors losing market share.
- Dynamics continuing to skew toward ambulatory from acute care settings.
- Opportunities created for Mach7's enterprise imaging products which serve both markets.



Complexity

- More complex reading environments and remote workforces becoming the norm.
- Enterprise imaging strategies require innovation and interoperability to give hospital networks and private groups a simplified image management and diagnostic viewing solution from any location.



Investment

- Global imaging IT investment returned to pre-pandemic levels.
- Mandates to invest in new technology for remote work.
- Opportunity to capitalise on replacement cycles along with providers' venture into multi-ology Enterprise Imaging.



Technology

- Imaging IT providers must support health systems in the realisation of many competing priorities including:
- Enterprise imaging
 - Public cloud
 - AI orchestration
 - Greater interoperability within increasingly complex provider networks.

Factors driving demand

- **Decisions increasingly driven by C-suite** with emphasis on enterprise efficiency, simplified procurement and cost savings.
- **Growing investment across non-acute providers.** Many imaging centres and ambulatory centres offer multi-disciplinary services, joint ventures with acute care space.
- **Consolidation of healthcare providers** and growing desire for regional clustering of procurement for centralised imaging IT.
- **Role of AI in optimising and driving value** across the clinical workflow and enhancing the patient care pathway. Impact will accelerate as AI market develops and greater downstream value is demonstrated from solutions.

Barriers to change

- **Financial ROI less well understood for enterprise-wide data management** compared to Radiology Departmental PACS.
- **Difficult and expensive transition from legacy “Managed service” providers** with many customers locked into long-term contracts.
- **Integration challenges with legacy vendors** many of which are not “standards based.”

Key Competitors and Market Share

World Market for Total Imaging IT		
Company	2022	
	Rank	%
GE HealthCare	1	15.4%
Philips	2	14.9%
Fujifilm	3	12.4%
Siemens Healthineers	4	12.1%
Change Healthcare	5	6.3%
AGFA Healthcare	6	5.1%
Canon Medical	7	3.1%
Sectra	8	2.9%
Merative	9	2.8%
Intelerad	10	2.4%
Others		22.6%
Total Market	\$5,232.4	
Source: Signify Research		
May-23		

NAM Market for Total Imaging IT		
Company	2022	
	Rank	%
Change Healthcare	1	15.0%
GE HealthCare	2	14.4%
Philips	3	14.3%
Fujifilm	4	9.2%
Siemens Healthineers	5	8.5%
AGFA Healthcare	6	7.4%
Merative	7	6.2%
Intelerad	8	5.0%
Sectra	9	3.3%
Visage	10	3.0%
Others		13.9%
Total Market	\$2,020.8	
Source: Signify Research		
May-23		

Growth across all markets is forecast to peak short-term (2023-2024), driven by the dovetail of the radiology replacement cycle, continued prioritisation of operational workflow tools and increased opportunities to upsell in a vendors radiology installed base as providers seek multi-ology Enterprise Imaging platforms.

Note: NAM refers to North America

Source: Signify Research, Imaging IT Core Report – World 2023

- **Enterprise First Strategy**

- VNA backend data management solution designed and built for entire healthcare network rather than the radiology department

- **Interoperable Platform**

- Works with existing and future hospital technology - allows image enablement of the EMR and integration of advanced clinical applications and tools, including AI

- **Tech Stack Independence**

- Promotes customer control of tech stack via Mach7 module or end-to-end imaging solution. Future-proof scalability; low GPU consumption

- **Unique Deployment Flexibility**

- Migration services - initially a strategy to secure business, now a valued service to preserve tech investment already made by hospital networks

- **'Top Performer' Product Rankings**

- Mach7's Viewer ranked #2 by independent customer survey (KLAS Research). Features include intuitive usability, advanced clinical workflow tools and diagnostic viewing

- **Zero Footprint Viewer**

- Instant access to patient medical images on any device via EMR or web browser without requirement for additional software or plugins

- **Cloud Compatibility**

- Robust data management architecture gives healthcare IT department the option to host system on-premise or via cloud connection

- **Security**

- Customers own their imaging data; Mach7 ensures product security via regular penetration testing and ISO certification



Build on Existing Work

Builds upon the substantial work done in the medical imaging sector to accept standard based information exchange. This allows stakeholders to utilise and exchange data across organisational boundaries.



Allow Anyone to Join

Provides a point of access to allow all types of healthcare stakeholders to participate with a complete medical record to include image availability. Regardless of the vendor used.



Innovative Technologies

Allows new and innovative technologies such as AI to enter the enterprise to overlay and build solutions that make use of the data.



Long-Term Scalability

Ensures variation around a broader set of use cases and provides long-term scalability for participants and end-users.

Disclaimer “forward looking” statements



Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“M7T”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD\$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.